PDE4-IN-13 

PDE4-IN-13 is a PDE4 inhibitor with an IC₅₀ of 1.56 μM. PDE4-IN-13 shows anti-inflammatory and antioxidant properties， and can be used for chronic obstructive pulmonary disease (COPD) research^[1].

PDE4-IN-13 (compound 6o) reducesTNF-α production induced by lipopolysaccharide (LPS) in RAW264.7 macrophages and malondialdehyde (MDA) production induced by Fe²⁺ in mouse lung homogenate. Meanwhile, PDE4-IN-13 shows outstanding abilities in reducing Fe³⁺ and complexing Fe^2+[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PDE4-IN-13 (compound 6o) (50 mg/kg and 100 mg/kg, i. p.) distinctly prevents LPS-induced serum levels of TNF-α in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

340.37

C₂₀H₂₀O₅

O=C(C1=CC=C(O)C(O)=C1)/C=C/C2=CC=C(OC)C(OCC3CC3)=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Youzhi Wang, et al. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD. Eur J Med Chem. 2023 Aug 5;256:115374.  [Content Brief]